US Stem Cell Research Policy

Johnston, Josephine; Zacharias, Rachel

doi:10.1016/b978-0-12-809880-6.00075-8

Principles of Regenerative Medicine 2019

DOI: 10.1016/b978-0-12-809880-6.00075-8

|View full text |Cite

US Stem Cell Research Policy

Josephine Johnston

Rachel Zacharias

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2021

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This practice has been controversial for decades in the United States, largely in the context of stem cell research, and cannot be conducted with federal funding. 10 Whatever one's beliefs regarding the moral status of the embryo, we need to recognize that supporting such research will be divisive in our society and should merit approval only when such research has compelling social value.…”

mentioning

confidence: 99%

The case for banning heritable genome editing

Botkin

2020

Genetics in Medicine

View full text Add to dashboard Cite

mentioning

confidence: 99%

The case for banning heritable genome editing

Botkin

2020

Genetics in Medicine

View full text Add to dashboard Cite

Economics of Beta-Cell Replacement Therapy

et al. 2019

View full text Add to dashboard Cite

Purpose of Review: Type 1 diabetes impacts 1.3 million people in the United States with a total direct lifetime medical cost of $133.7 billion. Management requires a mix of daily exogenous insulin administration and frequent glucose monitoring. Decision making by the individual can be burdensome. Recent Findings: Beta-cell replacement, which involves devices protecting cells from autoimmunity and allorejection, aims at restoring physiological glucose regulation and improve clinical outcomes in patients. Given the significant burden of T1D in the healthcare systems, cost-effectiveness analyses can drive innovation and policymaking in the area. Summary: This review presents the health economics analyses performed for donor-derived islet transplantation and the possible outcomes of stem cell-derived beta cells. Long-term cost-effectiveness of islet transplantation depends on the engraftment of these transplants, and the expenses and thresholds assumed by healthcare systems in different countries. Early health technology assessment analyses for stem cell-derived beta-cell replacement suggest manufacturing optimization is necessary to reduce upfront costs.

show abstract

Advancing Ethical Stem Cell Research with CRISPR

Neuhaus

Zacharias

2018

Curr Stem Cell Rep

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

US Stem Cell Research Policy

Cited by 4 publications

References 35 publications

The case for banning heritable genome editing

The case for banning heritable genome editing

Economics of Beta-Cell Replacement Therapy

Advancing Ethical Stem Cell Research with CRISPR

Contact Info

Product

Resources

About